Ohio: Once pegged as a blockbuster medicine for lowering LDL, long-acting small interfering RNA, Inclisiran failed to find any place in the recently released American Association of Clinical ...

Novartis added inclisiran to its pipeline after buying The Medicines Company – which had licensed the drug from Alnylam – for $9.7 billion in 2019, and will be hoping for a swift uptake in the ...

Swiss pharma major Novartis (NOVN: VX) is set to lay off 427 employees at its East Hanover, New Jersey, site as part of a ...

GP collective action in Kent has led to an agreement from the ICB to fund new locally-commissioned services, including for ...

Obesity is a raging conversation globally now, and manufacturing of generics will pick up after the patent expires.' ...

Repatha and Praluent are also facing the threat of competition from inclisiran, an RNAI interference drug originally developed by The Medicines Company that only needs to be delivered by injection ...

每天吃药、定期复查，血脂还是居高不下？高血脂，这一心脑血管疾病的「隐形杀手」，每年导致全球近400万人死亡。 而近期，《Nature ...

Allergan was running a long-term study on silicone breast implants. I had always wanted a more feminine body like the girls in the magazines, so I joined and got implants. They never followed up with ...

在全球生物医药领域，多肽和寡核苷酸（TIDES）疗法近期迎来了一系列突破性进展。诺华（Novartis）公司研发的siRNA降胆固醇药物——英克司兰钠（inclisiran），在亚洲的3期临床研究中显示出色的效果，药物能够在一年内仅需注射两次，帮助近80%的患者实现低密度脂蛋白胆固醇（LDL-C）达标。而177Lu-edotreotide作为一种靶向放射性疗法，最近也取得了重要成果，有望在治疗特定 ...